Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific
Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific
Body unavailable. Use the original source.
Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.